Ceribell Inc. has released a corporate presentation detailing recent developments in its AI-powered point-of-care EEG platform, designed for the detection and management of serious neurological conditions in acute care settings. The presentation highlights a U.S. annual addressable market estimated at over $2 billion and reports third-quarter 2025 revenue of $22.6 million, representing a 31% year-over-year increase. As of the end of the third quarter, Ceribell has 615 active accounts and achieved an 88% gross margin. The platform targets the diagnosis of both visible and non-convulsive seizures, particularly in critically ill patients where such conditions are often underdiagnosed. The content also addresses the limitations of conventional EEG systems in acute care and emphasizes the importance of timely seizure detection and intervention. You can access the full presentation through the link below.